FB1006
/ 4B Technologies, Peking University
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 28, 2023
Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
(clinicaltrials.gov)
- P4 | N=64 | Recruiting | Sponsor: Peking University Third Hospital
New P4 trial • Amyotrophic Lateral Sclerosis • CNS Disorders
1 to 1
Of
1
Go to page
1